Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Prospective, Double-Masked, Randomized, Multi-Center, Active-Controlled, Parallel Group Comparison Study Assessing the Ocular Hypotensive Efficacy of Reformulated PG324 Ophthalmic Solution in Subjects With Elevated Intraocular Pressure

NCT07082816 is registered in ClinicalTrials.gov with Alcon Research as lead sponsor.

NCT NCT07082816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07082816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Prospective, Double-Masked, Randomized, Multi-Center, Active-Controlled, Parallel Group Comparison Study Assessing the Ocular Hypotensive Efficacy of Reformulated PG324 Ophthalmic Solution in Subjects With Elevated Intraocular Pressure
Lead sponsor
Alcon Research
Phase
Phase 3
Overall status
Completed
Start date
September 2, 2025
Completion date
April 6, 2026
Enrollment
489 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open angle glaucoma